Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review.
Benjamin ChevalierLucie CordiezPauline RomanetThomas CunyJean-Christophe MaïzaJuliette AbeillonJulien ForestierThomas WalterOlivier GillyMaelle Le BrasSarra SmatiMarie Laure NunesAurore GeslotSolange GrunenwaldCéline MoulyGwenaelle ArnaultKathy WagnerEugénie KoumakisChristine Cortet-RudelliÉmilie MerlenArnaud JanninStéphanie EspiardIsabelle MorangeÉric BaudinMathias CavailleIgor TauveronMarie-Pierre TeissierFrançoise Borson-ChazotDelphine PrunierFrédérique SavagnerÉric PasmantSophie GiraudMarie-Christine VantyghemPierre GoudetAnne BarlierCatherine Cardot-BautersMarie-Françoise OdouPublished in: The Journal of clinical endocrinology and metabolism (2024)
The prevalence of MEN4 is low. PHPT and pituitary adenoma represent the main associated lesions, NETs are rare. Our results suggest a milder and later phenotype than in MEN1. Our observations will help to improve genetic counseling and management of MEN4 families.